[go: up one dir, main page]

DE60014239D1 - Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität - Google Patents

Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität

Info

Publication number
DE60014239D1
DE60014239D1 DE60014239T DE60014239T DE60014239D1 DE 60014239 D1 DE60014239 D1 DE 60014239D1 DE 60014239 T DE60014239 T DE 60014239T DE 60014239 T DE60014239 T DE 60014239T DE 60014239 D1 DE60014239 D1 DE 60014239D1
Authority
DE
Germany
Prior art keywords
fractions
linked
purification process
invention concerns
immunomodulating activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60014239T
Other languages
English (en)
Other versions
DE60014239T2 (de
Inventor
Dominique Bourel
Martine Bruley-Rosset
Frederic Dhainaut
Jacky Lirochon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FRACTIONNEMENT ET DE BIOTECHNO
Original Assignee
FRACTIONNEMENT ET DE BIOTECHNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9907153A external-priority patent/FR2794460A1/fr
Application filed by FRACTIONNEMENT ET DE BIOTECHNO filed Critical FRACTIONNEMENT ET DE BIOTECHNO
Application granted granted Critical
Publication of DE60014239D1 publication Critical patent/DE60014239D1/de
Publication of DE60014239T2 publication Critical patent/DE60014239T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/965—Chemistry: molecular biology and microbiology involving idiotype or anti-idiotype antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/822—Identified hapten
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60014239T 1999-06-07 2000-06-07 Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität Expired - Lifetime DE60014239T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9907153A FR2794460A1 (fr) 1999-06-07 1999-06-07 Procede de preparation de nouvelles fractions d'igg humaines possedant une activite immunomodulatrice
FR9907153 1999-06-07
FR9916632A FR2794461B1 (fr) 1999-06-07 1999-12-29 Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR9916632 1999-12-29

Publications (2)

Publication Number Publication Date
DE60014239D1 true DE60014239D1 (de) 2004-11-04
DE60014239T2 DE60014239T2 (de) 2005-08-25

Family

ID=26234979

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60014239T Expired - Lifetime DE60014239T2 (de) 1999-06-07 2000-06-07 Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität

Country Status (12)

Country Link
US (1) US6932969B1 (de)
EP (1) EP1059088B1 (de)
JP (1) JP2003519619A (de)
AT (1) ATE277635T1 (de)
AU (1) AU780138B2 (de)
CA (1) CA2376335A1 (de)
DE (1) DE60014239T2 (de)
DK (1) DK1059088T3 (de)
ES (1) ES2228425T3 (de)
FR (1) FR2794461B1 (de)
PT (1) PT1059088E (de)
WO (1) WO2000074717A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10127712A1 (de) * 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
FR2832155B1 (fr) * 2001-11-09 2004-07-09 Lab Francais Du Fractionnement Anticorps stimulant la production d'il-1ra
US20040101909A1 (en) * 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
EP1631314B1 (de) 2003-06-09 2011-08-03 Redox-Reactive Reagents L.L.C. Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations-reduktionsreaktionen
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
FR2939667B1 (fr) 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
CA3018235C (en) * 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2258727A1 (de) 2009-05-27 2010-12-08 Wezen Biopharmaceuticals S.r.l. A Socio Unico Immunglobulinzubereitung zur Behandlung einer Autoimmunerkrankung und Immunsystemstörungen
US20100330102A1 (en) 2009-06-26 2010-12-30 Wezen Biopharmaceuticals Srl A Socio Unico Immunoglobulin preparation for the treatment of hiv-1 infection
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011305306C1 (en) 2010-09-22 2016-02-18 Amgen Inc. Carrier immunoglobulins and uses thereof
CN106456743A (zh) 2014-02-21 2017-02-22 洛桑聚合联合学院 糖靶向性治疗剂
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3638296A1 (de) 2017-06-16 2020-04-22 The University Of Chicago Zusammensetzungen und verfahren zur herbeiführung einer immuntoleranz
WO2019133245A1 (en) * 2017-12-27 2019-07-04 The Johns Hopkins University Preventing cytokine release syndrome
KR20210010879A (ko) 2018-05-09 2021-01-28 더 유니버서티 오브 시카고 면역 관용 관여 조성물 및 방법
CN116159340A (zh) * 2022-12-16 2023-05-26 浙江大学 一种用于体积排阻色谱法的缓冲液

Also Published As

Publication number Publication date
US6932969B1 (en) 2005-08-23
DE60014239T2 (de) 2005-08-25
ES2228425T3 (es) 2005-04-16
AU5538700A (en) 2000-12-28
EP1059088A1 (de) 2000-12-13
FR2794461B1 (fr) 2004-01-23
JP2003519619A (ja) 2003-06-24
WO2000074717A1 (fr) 2000-12-14
EP1059088B1 (de) 2004-09-29
DK1059088T3 (da) 2005-02-07
AU780138B2 (en) 2005-03-03
PT1059088E (pt) 2005-02-28
ATE277635T1 (de) 2004-10-15
CA2376335A1 (fr) 2000-12-14
FR2794461A1 (fr) 2000-12-08

Similar Documents

Publication Publication Date Title
DE60014239D1 (de) Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität
RU2193413C2 (ru) Пептидные иммуногены для вакцинации и лечения аллергии
PT712863E (pt) Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69535243D1 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
NO913428D0 (no) Humant intra-acrosomalt sperma-antigen for anvendelse i en befruktningshindrende vaksine.
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
EP0493446A4 (en) Treatment of autoimmune disease
ATE145246T1 (de) Monoklonale antikörper zur induzierung von toleranz
FI903827A0 (fi) Foerfarande foer reducering av immunoglobulin e-responser.
AU626684B2 (en) Mouse monoglonal antibodies for post-exposure treatment of rabies
NO933394L (no) Omformede monoklonale antistoffer mot en immunoglobulin isotype
BR9305557A (pt) Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
ATE143377T1 (de) Schimäre immunoglobuline für cd4-rezeptoren
Wilkinson et al. Tolerogenic polyethylene glycol derivatives of xenogeneic monoclonal immunoglobulins
Pène et al. Induction of a cross-reactive idiotype dextran-positive antibody response in two IgH-Cb mouse strains treated with anti-J558 cross-reactive idiotype antibodies.
Cerny et al. Properties of anti-idiotypic T cell lines propagated with syngeneic B lymphocytes. I. T cells bind intact idiotypes and discriminate between the somatic idiotypic variants in a manner similar to the anti-idiotopic antibodies.
Poskitt et al. Internal image (Ab2β) anti-idiotype vaccines. Theoretical and practical aspects
KR960040375A (ko) 표피성장인자 수용체에 대한 면역반응을 유도하는 항-이디오타입 항체
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
Bozelka et al. Effects of anti-ε on total and specific IgE levels in adult mice
Riggott et al. Generating monoclonal antibodies to neuronal antigens
Hirano et al. Presence of an intrastrain cross-reactive idiotype on A/J antibodies of the IgE class specific for the p-azophenylarsonate group.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition